Shiraz E-Medical Journal

Published by: Kowsar

Potential Effect of Simvastatin as an Anti-Cancer Agent on SOX7 and SOX9 Expression in Prostate Cancer Cell Lines

Elham Arabizadeh 1 , Zohreh Mostafavipour 1 , 2 , Soudabeh Kavousipour 3 , Saeedeh Saeb 1 , Pooneh Mokarram 1 , * and Saeid Ghavami 4 , **
Authors Information
1 Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2 Recombinant Proteins Lab, Faculty of Advanced Biomedical Sciences, Shiraz, Iran
3 Department of Medical Biotechnology, School of Advanced Medical Science and Technologies, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada
Corresponding Authors:
Article information
  • Shiraz E-Medical Journal: February 28, 2019, 20 (2); e69057
  • Published Online: August 18, 2018
  • Article Type: Research Article
  • Received: April 3, 2018
  • Revised: June 28, 2018
  • Accepted: June 30, 2018
  • DOI: 10.5812/semj.69057

To Cite: Arabizadeh E, Mostafavipour Z, Kavousipour S, Saeb S, Mokarram P, et al. Potential Effect of Simvastatin as an Anti-Cancer Agent on SOX7 and SOX9 Expression in Prostate Cancer Cell Lines, Shiraz E-Med J. 2019 ; 20(2):e69057. doi: 10.5812/semj.69057.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195-200. doi: 10.1007/s00345-012-0824-2. [PubMed: 22476558].
  • 2. Ting H, Deep G, Agarwal C, Agarwal R. The strategies to control prostate cancer by chemoprevention approaches. Mutat Res. 2014;760:1-15. doi: 10.1016/j.mrfmmm.2013.12.003. [PubMed: 24389535]. [PubMed Central: PMC3923454].
  • 3. Moslemi MK, Lotfi F, Tahvildar SA. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience. Cancer Manag Res. 2011;3:227-31. doi: 10.2147/CMR.S18147. [PubMed: 21792331]. [PubMed Central: PMC3139483].
  • 4. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371-490. doi: 10.1002/cncr.20408. [PubMed: 15495199].
  • 5. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5. e189. doi: 10.1038/oncsis.2015.49. [PubMed: 26807644]. [PubMed Central: PMC4728678].
  • 6. de Boussac H, Pommier AJ, Dufour J, Trousson A, Caira F, Volle DH, et al. LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am J Cancer Res. 2013;3(1):58-69. [PubMed: 23359865]. [PubMed Central: PMC3555197].
  • 7. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol. 2003;23(4):1055-69. [PubMed: 12963986].
  • 8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508-19. doi: 10.1038/sj.leu.2402476. [PubMed: 11960327].
  • 9. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011;1(4):542-61. [PubMed: 21984972]. [PubMed Central: PMC3186052].
  • 10. Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol. 2015;193(2):403-13. doi: 10.1016/j.juro.2014.07.123. [PubMed: 25260832].
  • 11. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7(6):378-87. doi: 10.1177/1756287215597633. [PubMed: 26622322]. [PubMed Central: PMC4647137].
  • 12. Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935-41. doi: 10.3892/ijo.2011.1273. [PubMed: 22134829]. [PubMed Central: PMC3584570].
  • 13. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela T. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008;5(7):376-87. doi: 10.1038/ncpuro1146. [PubMed: 18542103].
  • 14. Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54(11):750-5. doi: 10.4111/kju.2013.54.11.750. [PubMed: 24255756]. [PubMed Central: PMC3830967].
  • 15. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011;336(2):496-505. doi: 10.1124/jpet.110.174870. [PubMed: 21059805].
  • 16. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59-71. [PubMed: 15784165].
  • 17. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-64. doi: 10.1038/sj.onc.1209085. [PubMed: 16288292].
  • 18. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70(3):979-87. doi: 10.1158/0008-5472.CAN-09-2370. [PubMed: 20103652].
  • 19. Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, et al. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016;126(5):1745-58. doi: 10.1172/JCI78815. [PubMed: 27043282]. [PubMed Central: PMC4855922].
  • 20. Stovall DB, Cao P, Sui G. SOX7: from a developmental regulator to an emerging tumor suppressor. Histol Histopathol. 2014;29(4):439-45. doi: 10.14670/HH-29.10.439. [PubMed: 24288056]. [PubMed Central: PMC4107680].
  • 21. Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, et al. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183(5):1645-53. doi: 10.1016/j.ajpath.2013.07.025. [PubMed: 24012678]. [PubMed Central: PMC3814686].
  • 22. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007;67(2):528-36. doi: 10.1158/0008-5472.CAN-06-1672. [PubMed: 17234760].
  • 23. Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X, et al. Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res. 2008;6(9):1421-30. doi: 10.1158/1541-7786.MCR-07-2175. [PubMed: 18819930]. [PubMed Central: PMC2652859].
  • 24. Karlic H, Thaler R, Gerner C, Grunt T, Proestling K, Haider F, et al. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genet. 2015;208(5):241-52. doi: 10.1016/j.cancergen.2015.03.008. [PubMed: 25978957]. [PubMed Central: PMC4503872].
  • 25. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene. 2004;23(26):4584-93. doi: 10.1038/sj.onc.1207603. [PubMed: 15077158].
  • 26. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68(6):1625-30. doi: 10.1158/0008-5472.CAN-07-5915. [PubMed: 18339840].
  • 27. Lee J, Lee I, Park C, Kang WK. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun. 2006;339(3):748-54. doi: 10.1016/j.bbrc.2005.11.075. [PubMed: 16316623].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments